In the realm of drug discovery in the US, the forecasted share of corresponding or leading authors in scientific publications shows a discernible upward trend from 2024 to 2028, climbing consistently each year. By 2028, this share is expected to reach 95.9%, up from a 94.43% projection in 2024, highlighting a significant increase over the period. As of 2023, this metric was documented at a slightly lower value, emphasizing the improvement anticipated in the forthcoming years.
- The year-on-year increase from 2024 to 2025 stands at approximately 0.53%.
- Progress from 2025 to 2026 also shows a rise of around 0.42%.
- The subsequent year from 2026 to 2027 projects a growth of 0.31%.
- The trend from 2027 to 2028 indicates another upward tick of 0.26%.
- Collectively over the five-year period, the Compound Annual Growth Rate (CAGR) highlights steady, albeit slowing, growth.
Future trends to watch include the potential influences of collaborative international research, open-access publication policies, and technological innovations such as AI in authorship habits and attribution in drug discovery. These factors could further impact leading author roles in the coming years.
